Pakistan Drug Regulator Hits Back At Drug Makers Over Suits
This article was originally published in PharmAsia News
Pakistan's drug regulatory agency has struck back at drug makers and importers by blaming them for causing the problems in their complaints by constantly dragging it into court over drug pricing issues.
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.